EUVIMEDEUVIMED entdecken
Open Access

Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center

Moe Ameri, Nagham Al Zubidi, Azadeh Razmandi, Andrew Whyte, Aung Naing, Nimisha A Patel, Dan S Gombos

Cureus · 18.06.2023

DOI: 10.7759/cureus.40597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 18.06.2023. Verfasst von Moe Ameri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Targeted cancer therapy (TCT) is a significant advancement in oncology with promising survival improvement in patients with cancer and remarkable effects on various cancers. There is evidence suggesting a connection between specific TCT classes and the occurrence of immune-related adverse events (irAEs). Our study aims to investigate the potential ocular toxicities of different classes of TCT, provide a better understanding of these toxicities, and aid in the future development of screening and management recommendations for ocular irAEs. DESIGN: Retrospective observational case series. PARTICIPANTS: Only ocular immune-related AEs were included in the study; patients on TCT who received a new ophthalmic diagnosis were seen at the MD Anderson Cancer Center. METHODS: Between 2010 and 2019, we retrospectively reviewed the medical records of 6,354 patients on TCT at a large US tertiary cancer center. Results: The criteria for data analysis were met by 1861 patients. TCT was associated with a wide range of class-specific ocular irAEs. There was a statistically significant correlation between ocular toxicity with polytherapy with a p-value of

Schlagwörter

Stichwörter der Autor:innen

immune-related adverse events (iraes)immunotherapiesocular iraesocular toxicitytargeted cancer therapy

Autor:innen und Institutionen

  • Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, USA.
  • Investigational Cancer Therapeutics / Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ophthalmology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.

Zitieren

APA

Ameri, M., Al Zubidi, N., Razmandi, A., Whyte, A., Naing, A., Patel, N. A., & Gombos, D. S. (2023). Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center. Cureus. https://doi.org/10.7759/cureus.40597

Vancouver

Ameri M, Al Zubidi N, Razmandi A, Whyte A, Naing A, Patel NA, et al. Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center. Cureus. 2023. doi:10.7759/cureus.40597

BibTeX
@article{Ameri2023,
  author = {Ameri, Moe and Al Zubidi, Nagham and Razmandi, Azadeh and Whyte, Andrew and Naing, Aung and Patel, Nimisha A and Gombos, Dan S},
  title = {Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center},
  journal = {Cureus},
  year = {2023},
  doi = {10.7759/cureus.40597}
}
Kostenlos starten →